OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

被引：39

作者：

Aghajanian, C.

Finkler, N. J.

Rutherford, T.

Smith, D. A.

Yi, J.

Parmar, H.

Nycum, L. R.

Sovak, M. A.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Florida Hosp, Inst Canc, Florida Hosp Gynecol Oncol, Orlando, FL USA

[3] Yale Univ, Sch Med, New Haven, CT USA

[4] Northwest Canc Specialists, Vancouver, WA USA

[5] Genentech Inc, San Francisco, CA 94080 USA

[6] Forsyth Reg Canc Ctr, Winston Salem, NC USA

来源：

关键词：

D O I：

10.1200/jco.2011.29.18_suppl.lba5007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA5007

引用

页数：1